BNET Industries
Market Cap:$489.1M
Last Fiscal Year Sales:$423.1M
- Public
- US
Dow Jones Description
USANA develops and manufactures high quality nutritional and personal care products that are sold directly to Preferred Customers and Associates throughout the United States, Canada, Australia, New Zealand, Hong Kong, Japan, Taiwan, South Korea, Singapore, Malaysia, Mexico, Philippines and the United Kingdom.
Number of Employees 948
Contact Information
3838 Parkway Blvd
Salt Lake City, Utah 84120-6336
(801) 954-7100
Peer Companies
NAICS Code Medicinal and Botanical Manufacturing: 325411
Recent Events
-
USANA Health Sciences Review - Is USANA A Good Business Opportunity To Be Involved With?
-
USANA Health Sciences Announces FY09 Q3 Results
-
USANA Launches Probiotic Plus
-
BRIEF-RESEARCH ALERT-Jefferies raises Nu Skin, USANA to buy
-
Thousands Flock to USANA Health Sciences 17th Annual
-
USANA Health Sciences Announces FY09 Q2 Results
News & Analysis
Filter by
finance and usana health sciences inc. - All News and Analysis
Gull Holdings Reaffirms Offer to Purchase Publicly-Held Shares of USANA Health Sciences, Inc. at $26.00 per Share
SALT LAKE CITY -- Gull Holdings, Ltd. and Unity Acquisition Corp. today reaffirmed their offer to purchase the outstanding shares of USANA Health Sciences, Inc. (NASDAQ:USNA) at $26.00 per share after USANA's announcement of preliminary second quarter 2008 results and the filing by USANA with the SEC of an amended...
Has added USANA Health Sciences Inc. to their watch list.
M2 PRESSWIRE-11 January 2008-The Maybach Financial Group: Has added USANA Health Sciences Inc. to their watch list.C1994-2008 M2 COMMUNICATIONS LTD RDATE:11012008 Maybach Financial Group is a syndicate of financial analysts, with a core group representing over 250 years of...
Earnings roundup
Usana Usana Health Sciences Inc., based in Salt Lake City, reported net income of $10.2 million, or 55 cents per share, for the third fiscal quarter ended Sept. 29. That compares with $11.3 million, or 68 cents per share, for the same quarter in 2006. Sales...
Usana's shares subject to delisting by Nasdaq
Usana Health Sciences Inc. said Wednesday that Nasdaq has notified it that its quarterly report on Form 10-Q is considered incomplete because the financial information in the form was not reviewed by an independent auditor. Nasdaq told the Salt Lake-based company that its shares are subject to delisting....
Earnings roundup
Several companies, including some based in Utah or with ties to the state, reported quarterly earnings results on Tuesday. Wells Fargo Rising core deposits and loans boosted first-quarter income at Wells Fargo & Co. 11 percent, despite growing problems in its subprime mortgage portfolio. ...
Thursdays Stock to Watch: ERUG! February 8, 2007.
M2 PRESSWIRE-8 February 2007-Stock Market Alerts LLC: Thursdays Stock to Watch: ERUG! February 8, 2007C1994-2007 M2 COMMUNICATIONS LTD RDATE:08022007 Miami, FLA. - Stock Market Alert's performance stock list includes: ER Urgent Care Centers (OTC: ERUG), FEI (NASDAQ: FEIC), EpiCept Corporation (NASDAQ:...
Thursday Morning Stock Report! October 19, 2006.
M2 PRESSWIRE-19 October 2006-Stock Market Alerts LLC: Thursday Morning Stock Report! October 19, 2006C1994-2006 M2 COMMUNICATIONS LTD RDATE:19102006 Miami, FLA. - Stock Market Alert's performance stock list includes: ER Urgent Care Centers (OTC: ERUG), Grant Life Sciences Inc. (OTCBB: GLIF), Primedex...
- 1
Industry Transcripts by Seeking Alpha
-
Avanir Pharmaceuticals F4Q09 (Qtr End 09/30/2009) Earnings Call Transcript
on Nov 24, 2009about AVNR
-
Palatin Technologies F1Q10 (Qtr End 9/30/09) Earnings Call Transcript
on Nov 16, 2009about PTN
-
Flamel Technologies SA Q3 2009 Earnings Call Transcript
on Nov 16, 2009about FLML
-
NexMed Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about NEXM
-
InterMune, Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about ITMN
Glass Door
USANA Health Sciences
IndustryTop Rated
- How NOT to Write a Biotech Press Release: Just Ask Epeius 5 votes
- Biogen Idec's Social Media Ties Save Tysabri Again; FDA Watching 3 votes
- More Tysabri Problems; Time for a Biogen-Idec Credibility Check 3 votes
- Teva, In Turnabout, Sues to Protect Its Multiple Sclerosis Drug Copaxone 3 votes
- Why J&J's Stelara Launch Should Target Dermatologists First 3 votes

